Ocugen Inc (OCGN)
$1.64
0.02 (1.20%)
OCGN Stock Quote Delayed 30 Minutes
Ocugen Has a Longer Road To Paying off Than People Think
Ocugen seems to have delivered good news in recent days, yet OCGN stock is right back where it started. Does that create a buying opportunity?
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
422.02M
PE Ratio
-6.83
EPS
-0.24
Volume (Avg. Vol.)
3.11M
Day's Range
$1.60 - $1.69
52-Week Range
$0.35 - $2.11
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Investors are digesting what big moves in Dogecoin and SafeMoon mean for the market.
OCGN Stock: Why Red-Hot Ocugen Is Plunging Again Today
Ocugen (OCGN) stock taking a beating on Friday following the release of the biopharmaceutical company's earnings report for Q1 2021.
Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance
OGCN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators.
Ocugen Stock Is a Risky Proposition Despite Its High Valuation
OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? Investors are closely watching Covid-19 vaccine makers like OCGN stock this morning.
OCGN Stock: Why Ocugen Shares Are Stumbling Again Today
Ocugen insiders have been selling shares ahead of Friday's earnings report. OCGN stock had touched a six-month high to start off the week.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday right with a look at the biggest pre-market stock movers that investors need to know about today.
Why Ocugen Stock Continues to Be a Great Short Opportunity
No U.S. government official has made positive comments about approving Covaxin and the Covaxin trials do not seem to meet the FDA's preferences. OCGN stock is a short.
Don’t Chase Ocugen Stock Without Reading the Fine Print
OCGN stock has soared on positive vaccine data. But investors must remember that Ocugen's market and experience are sharply limited.
Ocugen Looks Perched and Ready to Blow Through $18
Ocugen had a strong April gaining a whopping 87% for the month. OCGN stock is now up 313% on the year. It seems $18 is just around the corner.
Stick With Ocugen As Its Covid-19 Vaccine Is the Real Deal
Covid-19 vaccine candidate Covaxin may inhibit transmissions, and OCGN stock traders should appreciate the promising recent clinical results.
Midday Market Update: The 10 Most Active Stocks Monday
Monday is half over and we're keeping up with trading today in our midday market update for the most active stocks to keep an eye on.
OCGN Stock: The Big Study News Shooting Ocugen Shares Higher Today
Ocugen (OCGN) stock is soaring on Monday after announcing positive data concerning its Covaxin vaccine candidate for the novel coronavirus.
If You Have Ocugen Stock, Now’s the Time to Take Profits
OCGN stock earlier seemed like a great play on a Covid-19 resurgence. But this narrative is not turning out so well.
Despite Covaxin News, Ocugen Stock Remains a Long-Shot for US Use
Yet, there's little to indicate it will obtain FDA approval. In addition, there's plenty suggesting that the U.S., already oversupplied when it comes to vaccines, has little need for Covaxin. In short, with more to make a bear case than a bull case, tread carefully with OCGN stock.
Midday Market Update for Friday: The 10 Most Active Stocks Today
We're approaching the end of trading for the week and InvestorPlace is looking at the most active stocks in our midday market update.
Midday Market Update: The 10 Most Active Stocks Today
Wednesday is halfway over and that means it's time for investors to check in on a midday market update of the most active stocks.
The Reasons to Avoid OCGN Stock Keep Piling Up
OCGN stock got a bump on Phase 3 results but was met with market skepticism following its subsequent strategic moves.
A Couple Of Shots in the Arm for Ocugen Stock
Off and on the price chart, OCGN stock is setting itself up for big things that should have the attention of bullish investors.
